Baker Bros. Reports 7.31M Shares in Edgewise Therapeutics (EWTX)

Rhea-AI Filing Summary

Edgewise Therapeutics, Inc. received an Amendment No. 1 to a Schedule 13G filed by Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker and Felix J. Baker reporting aggregate beneficial ownership of 7,305,940 shares of common stock, representing 6.9% of the 105,200,221 shares outstanding used for the calculation. The filing states the Adviser has sole investment and voting power over those shares through management agreements with two funds, Baker Brothers Life Sciences, L.P. and 667, L.P., which directly hold 6,762,577 and 543,363 shares respectively. The disclosure is presented as an amendment and certifies the securities are held in the ordinary course of business and not to change or influence control of the issuer.

Positive

• Transparent disclosure of beneficial ownership and voting/dispositive power by the Adviser
• Detailed breakdown showing the two funds' direct holdings (6,762,577 and 543,363 shares)
• Clear certification that the shares are held in the ordinary course and not to change control

Negative

• None.

Insights

Securities Analyst

TL;DR: Baker Bros. reports a 6.9% stake via managed funds, with Adviser holding sole voting and dispositive power.

The amendment clarifies beneficial ownership structure: the Adviser exercises sole investment and voting discretion over 7,305,940 shares held by two funds, using 105,200,221 shares outstanding as the denominator. This level of ownership is below typical 10% activist thresholds but is material enough to warrant investor attention because it signals a significant minority stake and active portfolio allocation. The filing contains no statements of intent to influence control and certifies ordinary-course holdings, consistent with passive strategic positioning by an investment adviser.

Corporate Governance Expert

TL;DR: Disclosure properly identifies control lines and fund holdings; no indication of coordinated group action or control intent.

The Schedule 13G/A identifies the reporting persons, the funds holding the shares, and the Adviser as having sole voting and dispositive power through management agreements. The filing indicates no shared voting power and explicitly states the holdings are not for the purpose of changing control. Signatures from the Adviser and individuals provide standard certifications. Absent additional exhibits or intent language, the disclosure reads as routine beneficial-ownership reporting under the Exchange Act.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Edgewise Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

28036F105

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 28036F105

1

Names of Reporting Persons

Baker Bros. Advisors LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 7,305,940.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 7,305,940.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,305,940.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.9 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP No. 28036F105

1

Names of Reporting Persons

Baker Bros. Advisors (GP) LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 7,305,940.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 7,305,940.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,305,940.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.9 %

12

Type of Reporting Person (See Instructions)

HC, OO

SCHEDULE 13G

CUSIP No. 28036F105

1

Names of Reporting Persons

Julian C. Baker

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 7,305,940.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 7,305,940.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,305,940.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.9 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 28036F105

1

Names of Reporting Persons

Felix J. Baker

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 7,305,940.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 7,305,940.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,305,940.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.9 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Edgewise Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 1715 38th St., Boulder, CO, 80301
Item 2.
(a)	Name of person filing: This Amendment No. 1 to Schedule 13G amends the previously filed Schedule 13G filed by Baker Bros. Advisors LP (the "Adviser"), Baker Bros. Advisors (GP) LLC (the "Adviser GP"), Julian C. Baker and Felix J. Baker (collectively, the "Reporting Persons"). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect. This Amendment No. 1 is being filed jointly by the Reporting Persons.
(b)	Address or principal business office or, if none, residence: The business address of each of the Reporting Persons is: c/o Baker Bros. Advisors LP 860 Washington Street, 3rd Floor New York, NY 10014 (212) 339-5690
(c)	Citizenship: The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 28036F105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Items 5 through 9 and 11 of each of the cover pages to this Amendment No. 1 are incorporated herein by reference. Set forth below is the aggregate number of shares of Common Stock ("Common Stock") of Edgewise Therapeutics, Inc. (the "Issuer") directly held by each of Baker Brothers Life Sciences, L.P. ("Life Sciences") and 667, L.P. ("667", and together with Life Sciences, the "Funds") which may be deemed to be indirectly beneficially owned by the Reporting Persons. The percentage of beneficial ownership for each of the Reporting Persons reported herein and the information set forth below is based on 105,200,221 shares of Common Stock outstanding as of April 30, 2025, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on May 8, 2025. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Pursuant to the management agreements, as amended, among the Adviser, the Funds and their respective general partners, the Funds' respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds' investments and voting power over investments. The Adviser GP is the sole general partner of the Adviser. The Adviser GP, Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds.
(b)	Percent of class: The Funds beneficially own 7,305,940 shares of Common Stock or 6.9% of the outstanding Common Stock. 667 beneficially owns 0.5% and Life Sciences beneficially owns 6.4% of the outstanding Common Stock.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 667 directly holds 543,363 shares of Common Stock and Life Sciences directly holds 6,762,577 shares of Common Stock.
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 667 directly holds 543,363 shares of Common Stock and Life Sciences directly holds 6,762,577 shares of Common Stock.
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. The information in Item 4 is incorporated herein by reference.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Baker Bros. Advisors LP

Signature:	/s/ Scott L. Lessing
Name/Title:	Scott L. Lessing/ President, Baker Bros. Advisors (GP) LLC, its general partner
Date:	08/14/2025

Baker Bros. Advisors (GP) LLC

Signature:	/s/ Scott L. Lessing
Name/Title:	Scott L. Lessing/ President
Date:	08/14/2025

Julian C. Baker

Signature:	/s/ Julian C. Baker
Name/Title:	Julian C. Baker
Date:	08/14/2025

Felix J. Baker

Signature:	/s/ Felix J. Baker
Name/Title:	Felix J. Baker
Date:	08/14/2025

FAQ

How many Edgewise Therapeutics (EWTX) shares does Baker Bros. report owning?

The reporting persons disclose aggregate beneficial ownership of 7,305,940 shares of EWTX.

What percentage of EWTX does the 7,305,940 shares represent?

The filing states this represents 6.9% of the 105,200,221 shares outstanding used for the calculation.

Which entities directly hold the reported Edgewise shares?

The shares are directly held by Baker Brothers Life Sciences, L.P. (6,762,577 shares) and 667, L.P. (543,363 shares).

Who has voting and dispositive power over the reported shares?

Baker Bros. Advisors LP (the Adviser) is reported to have sole voting and sole dispositive power over the 7,305,940 shares under the management agreements.

Does the filing say Baker Bros. intends to change or influence control of Edgewise?

No. The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.